原发性痛经的治疗药物和治疗靶点研究进展  

Research progress of the drugs and targets for treatment of primary dysmenorrhea

作　　者：迟晓丽 刘国云[1] 周文霞[1] 张永祥[1] 刘超[2] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850 [2]军事医学科学院卫生学环境医学研究所,天津300050

出　　处：《军事医学科学院院刊》2007年第5期470-473,共4页Bulletin of the Academy of Military Medical Sciences

基　　金：国家重点基础研究发展规划("973"计划)项目(2004CB518907);国家自然科学基金项目(90709012)

摘　　要：原发性痛经是妇女常见的一种疾病,其发病机制复杂,可能与内分泌失调、子宫收缩异常以及子宫缺血、缺氧等原因有关。目前,原发性痛经的治疗药物主要以非甾体抗炎药(non-steroidal anti-inflammatory drugs,NSAIDs)及选择性COX-2抑制剂为主。但这些药物存在消化系统和心血管系统等不良反应,限制了其在临床的广泛应用。因此近年来人们开始重视研究开发新的高效低毒的原发性痛经治疗药物。本文对近年来原发性痛经治疗药物及治疗靶点的研究进展作一综述。Primary dysmenorrhea is a common disease among young women. Its pathogenesis is very complicated and probably closely related to endocrine unbalance, abnormal uterine contractility, uterine ischemia or hypoxia. Non-steroidal anti-inflammatory drugs （NSAIDs） and selective COX-2 inhibitors are currently the main drugs for treatment of primary dysmenorrhea. However, side effects of these drugs on the digestive system and cardiovascular system limit their clinical use. Therefore people begin to pay attention to searching for new drugs and targets for the treatment of primary dysmenorrhea with high potency and low toxicity. The advance in this area is reviewed in this article.

关 键 词：原发性痛经 治疗 发病机制 

分 类 号：R984[医药卫生—药品]